Glaucoma Therapeutics Market Demand, Developments, Industry Opportunities and Industry Research Report

Glaucoma is a disease of eye which is caused by excessive increase of fluid pressure within the eye. Glaucoma is caused due to mechanical compression or decreased blood flow in the optic nerve of the patient’s eye. If not treated properly, it may lead to mild loss of vision and even blindness. Treatment of glaucoma includes laser therapies, pharmaceutical drugs and surgical procedures.

Ocular hypertension is one of the major causes due to which glaucoma occurs in patients. Glaucoma mostly occurs at the age over 40, but it may also occur in children, young adults, and infants. Diagnosis of glaucoma can be done through a simple eye examination with the help of tonometry, an instrument used for measuring intraocular pressure, by an ophthalmologists and optometrist. Prevention of glaucoma is difficult; however, if diagnosed and treated at an early stage, the disease can be controlled by using eye drops prescribed by doctor, microsurgery or by laser surgery. Glaucoma can damage the vision of the affected eye permanently; in first stage it decreases the peripheral vision and if not treated, it can lead to blindness.

Request to Get the Sample Pages at:

Some of the major factors driving the growth of glaucoma therapeutics market are aging population of developed countries, development of advanced glaucoma drug delivery devices and rising global healthcare expenditures. Stringent government regulation and marketing approval, side effects of glaucoma medications and long development process of the glaucoma products are some of the major factors restraining the growth of global glaucoma therapeutics market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=glaucoma-therapeutics-market

North America was the largest glaucoma therapeutics market in 2014, attributed to high per capita expenditure on healthcare in this region. It is followed by Europe and Asia-Pacific. Asia-Pacific region is also the fastest growing glaucoma therapeutics market, owing to the aging population of Japan coupled with the increasing healthcare expenditure of developing countries, such as India and China. Asia-Pacific glaucoma therapeutics market is further expected to witness growth and surpass North America market in terms of largest market during the coming years.

Some of the major competitors in global glaucoma therapeutics market are Pfizer Inc., Allergen Inc., Novartis A.G., Merck & Co. Inc., Aerie Pharmaceuticals Inc., Inotek Pharmaceuticals Corp., Carl Zeiss Meditec Inc., Acadia Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., NicOx SA, Santen Pharmaceuticals Co. Ltd., Otsuka Holdings Co. Ltd., SIFI SpA, and Valeant Pharmaceuticals International Inc.

Read More

Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Analysis by Stages, Drug Class, Company Profile, Phase of Development, and Discovery Stage Insights

The global chronic lymphocytic leukemia therapeutics market is expected to create more opportunities in oncology due to promising pipeline and positive clinical data of drug candidates. The existing drugs for the treatment of chronic lymphocytic leukemia is the be most effective treatment. The American Cancer Society, and other regulatory bodies are supporting the chronic lymphocytic leukemia therapeutics market by providing funding and grants. The market is being driven by different factors such as rising awareness for the cancer treatments, high demand for safe and effective medications, technologies advancements, and increasing prevalence of cancer.

Chronic lymphocytic leukemia is a type of gradually developing leukemia that affects the development of B lymphocytes (also known as B cells). On the other hand, B cells are specialized white blood cells, which produce immunoglobulins (also called antibodies) under normal conditions, and help to protect the human body against infections and diseases. In patients with chronic lymphocytic leukemia, lymphocytes undergo a malignant change and become leukemic cells.

Request to Get the Sample Pages at: 

Ono Pharmaceutical and Bristol-Myers Squibb are in the process of developing Opdivo for the treatment of chronic lymphocytic leukemia. Genentech is developing Atezolizumab, also known as MPDL 3280A, for chronic lymphocytic leukemia therapeutics, which is in Phase II stage. Atezolizumab is a monoclonal antibody targeting programmed cell death-1 ligand 1 (PD-L1). PD-L1 plays an important role in suppressing the immune system triggered by the cancer. PD-L1 acts by reducing the proliferation of antigen-specific CD8+ T-cells and controlling the accumulation of foreign antigen-specific T-cells.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=chronic-lymphocytic-leukemia-therapeutics-market

The chronic lymphocytic leukemia is more prevalent in North America, making the region to be the largest revenue contributor, globally. The U.S. contributed the largest revenue to the North American market in year 2016, and it is expected to remain the largest market across the globe, during the forecast period.

Some of the key players operating in the chronic lymphocytic leukemia therapeutics market are GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Biogen Inc., AbbVie, Inc., Teva Pharmaceuticals Limited, Gilead Sciences, Inc., Novartis AG, and Johnson & Johnson.

Read More

Nuclear Medicine (Radiopharmaceuticals) Market by Overview, Growth Opportunities, Manufacturing Cost Structure Analysis, Outlook and Industry Insights Forecast to 2024

The global nuclear medicine/radiopharmaceuticalsmarket is growing significantly due to increasing prevalence of cancer and cardiovascular diseases, and advances in nuclear medicine imaging procedures. High demand of nuclear medicines in emerging economies and potential radiopharmaceuticals in the pipeline create ample opportunities for the nuclear medicine/radiopharmaceuticals market to grow at a considerable rate in the coming years.

The advances in neurological applications and development of new products by the companies are supporting to address the demand for cost effectiveness of radiopharmaceuticals. Nuclear medicine imaging procedures are non-invasive and can be used for the treatment of several diseases, such as cancers, cardiovascular diseases, and neurological disorders.

Request to Get the Sample Pages at: 

The nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and region. On the basis of type, the nuclear medicine/radiopharmaceuticals market can be segmented as diagnostics and therapeutics. The diagnostics segment leads the nuclear medicine/radiopharmaceuticals market. The diagnostics segment can be further categorized into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). SPECT segment will be leading the nuclear medicine/radiopharmaceutical diagnostics market in the coming years due to its wider availability and less cost. The therapeutics segment can be further categorized into beta emitters, alpha emitters, and brachytherapy isotopes. The beta emitters will be the leading segment in the global nuclear medicine/radiopharmaceutical therapeutics market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nuclear-medicine-market

Geographically, North America will be leading the global nuclear medicine/radiopharmaceuticals market in the coming years due to increasing prevalence of cancer, ready availability of radiopharmaceuticals, popularity of nuclear medicine among physicians, and technological advancements.

Asia-Pacific is the fastest growing region in the global nuclear medicine/radiopharmaceuticals market. The major reasons for the fastest growth in the region are increasing healthcare expenditure, and rising awareness of radiopharmaceuticals among healthcare providers. Moreover, Japan will be leading the nuclear medicine/radiopharmaceuticals market in Asia-Pacific region in the coming years.

Some of the major players operating in the global nuclear medicine/radiopharmaceuticals market are GE Healthcare, Bayer Healthcare, Cardinal Health Inc., Eczacibasi-Monrol Nuclear Products, Bracco Imaging S.p.A, Nordion Inc., Lantheus Medical Imaging Inc., Advanced Accelerator Applications S.A, Mallinckrodt plc, and IBA Molecular Imaging.

Read More

Diabetic Nephropathy Market Opportunities by Types, Demand, Top Manufactures and Application in Grooming Regions

The increase in research and development funds for drug discovery followed by growing awareness of kidney-related disorders, and diabetes are the major factors driving the expansion of the global diabetic nephropathy market.

Diabetes is a disease defined by high blood sugar level, caused by inappropriate functioning of the pancreas (the organ which secretes insulin in the body). Nephropathy means kidney impairment or damage. Diabetic nephropathy is the impairment or damage to the kidneys caused by diabetes.

It is a disease which affects the kidney glomerulus and one of the most major issues for diabetic patients. Not only the person with diabetes has to undergo kidney impairment, but also the acute cases of diabetic nephropathy could lead to kidney miscarriage. The disease affects the kidneys in a way that makes it futile. Progressive growth in proteinuria and failure in renal function, hypertension, and high risk of cardiovascular disease are the major side effects of chronic diabetic nephropathy. Blood pressure (BP) control is necessary in minimizing the progression of diabetic nephropathy. Irrespective of the agent used, lower blood pressure in type II diabetics could slow down the start and progression of diabetic nephropathy.

Request to Get the Sample Pages at:

On the basis of mode of treatment, the global diabetic nephropathy market is segmented into disease modifying therapies and others. Disease modifying therapies is further categorized into diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, renin inhibitors, calcium channel blockers, connective tissue growth factor inhibitors, monocyte chemoattractant proteins inhibitor, G protein-coupled receptors and endothelin (a receptor antagonist).

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-nephropathy-market

Various government programs are spreading cognizance about diabetes and related renal complications in North America. For example, the National Kidney Disease Education Program (NKDEP) is one of the most important programs organized by the U.S. government, for growing awareness about the various kidney diseases.

Lack of complete therapeutic management for diabetic nephropathy, longer approval time for drugs as well as, harsh regulatory requirements are hampering the market growth of global diabetes nephropathy market.

Some of the major competitors in the global diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Sanofi, Eli Lilly and Company, Reata Pharmaceuticals, Inc., Bayer AG, AbbVie Inc., and Mitsubishi Tanabe Pharma Corporation.

Read More

Biopharmaceuticals Market Size, Share, Development, Growth and Demand

View more on edocr

Read More

Asthma Market to Witness the Highest Growth Globally in Coming Years

Asthma is a respiratory condition, where the airways become inflamed and narrow, which can cause a serious and incurable condition if left untreated. Breathlessness, wheezing and coughing are some of the symptoms of asthma and it can be controlled by avoiding triggers and with the help of drug therapy. Environmental triggers may vary from consumer to consumer but it can include exercise, smoke, cold air and other allergens such as pollen, dust mites, and infections. The wheezing in asthma begins when the chemicals present in the lungs overreact to the dust mites, cold air and exercise.

According to Centers for Disease Control and Prevention (CDC), asthma is an ordinary chronic airway disorder which is characterized by swelling of air passages that convey air from mouth and nose to lungs. Asthma is caused generally due to allergies leading to inflammation of lungs. GlaxoSmithKline Pharmaceuticals Limited and Novartis AG are developing once-a-day combination products that are longer acting than currently available drugs and more suitable for patients due to its advantage of being taken only once a day.

Request to Get the Sample Pages at: 

Based on drug class, the global asthma market can be categorized bronchodilators, combination therapies, mast cell stabilizers, leukotriene antagonists and immunosuppressants. On the basis of route of administration, the global market is segmented into oral, inhaled and other route of administrations.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=asthma-market

Daily exposure to hazardous working environment, influx of pollutants in the air, increase in population susceptible to indoor air pollutants, increase in disposable income, increasing population of smokers, improved healthcare facility, and growing aging population are some of other the major factors that are driving the growth of asthma market. Factors that are restraining the growth of asthma market are high cost of asthma treatment, patent expiry of many best-seller brands and long treatment continuation. Additionally, lack of diagnostic tools for reliable asthma diagnosis in young children is also limiting the growth of global asthma market.

Some of the major competitors of global asthma market are, Ono Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. Merck & Co., Inc., Astrazeneca plc, Sunovion Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim GmbH, Koninklijke Philips N.V., and F. Hoffmann La-Roche Ltd.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Breast Cancer Market Comprehensive Analysis of Market Trends, Technological Advancements, Company Profile and Growth Opportunities

Cancer is a disease characterized by uncontrolled growth of cell. There are about 100 different types of cancer and each is classified by the type of cell where it occurs and affects. Breast cancer is mostly prevalent in women, however, breast cancer in men is rare. It is frequently diagnosed in aged women and one of the leading causes of death among them. Some of the most common types of breast cancer are ductal carcinoma in situ (DCIS), lobular carcinoma and invasive ductal carcinoma.

DCIS, also known as intraductal carcinoma, begins in the lining of the milk ducts. Milk ducts are thin tubes carrying milk from lobules of the breast to the nipple. Lobule carcinoma originates in the lobules or milk glands of the breast. Invasive ductal carcinoma is the most common type of breast cancer. It starts in a milk duct of the breast, ruptures through the wall of the duct and grows into the fatty tissue of the breast. It spreads to other parts of body through bloodstream.

Request to Get the Sample Pages at:

North America accounts the largest global breast cancer market followed by Europe. The U.S., followed by Canada, is the largest market for breast cancer in North America. Key driving factor for this market is increasing prevalence of breast cancer in the region. Germany, France and the U.K. are some of the largest markets for breast cancer in Europe region. However, Asia-Pacific represents the fastest growing region in the global breast cancer market. This is due to improving healthcare infrastructure and increasing awareness among people about breast cancer. In developing countries, such as China and India, government has launched several programs and initiatives which increase awareness about the disease. It has led to significant rise in demand of breast cancer diagnostics and therapeutics for disease management. In addition, less stringent wages and availability of skilled labor attracts manufacturing companies to invest in developing countries. 

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=-breast-cancer-market

Increasing prevalence of the disease is a key driving factor for the global breast cancer market. Increasing awareness among people about the disease and rising number of geriatric women around the world are also supporting the growth of global breast cancer market. In addition, increased research in the field of oncology and development of biomarker has also fueled the growth of global breast cancer market. Increasing demand of advanced therapeutic drugs and extensive drug pipeline holds immense potential to the growth of the global breast cancer market.

Some of the major competitors in the market are Astrazeneca PLC, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Novartis AG, Sanofi-Aventis. Pfizer, Inc., Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd.

Read More

Bile Duct Cancer Therapeutics Market Has Been Classified on the Basis of Disease Indication, Treatment Type and Geography

Bile duct cancer is also known as cholangiocarcinoma. It involves the presence of mutated epithelial cells originated in the bile ducts. However, the cause of bile duct cancer (cholangiocarcinoma) is not certain. There are some factors that can increase the chances of developing bile duct cancer (cholangiocarcinoma).

The most common symptoms of bile duct cancer (cholangiocarcinoma) include abdominal pain, abnormal liver function, generalized itching, weight loss, discoloration of stool and urine, etc. The risk factor of bile duct cancer (cholangiocarcinoma) include liver fluke infections, cholangitis and exposure to thorium dioxide. According to American Society of Clinical Oncology (ASCO), less than 3,000 people are affected with the disease, every year, in the U.S. Also, according to Cancer Research UK, about 1,600 people are affected by the disease, every year, in the U.K. The existing treatment options for bile duct cancer (cholangiocarcinoma) are mainly dominated by generics and off-label drugs, and provide only symptomatic relief. 

Request to Get the Sample Pages at:

The global bile duct cancer therapeutics market has been classified on the basis of disease indication, treatment type and geography. Based on disease indication, the global bile duct cancer therapeutics market has been segmented into perihilar (hilar) bile duct cancers, distal bile duct cancers, and intrahepatic bile duct cancers. Based on treatment type, the global bile duct cancer therapeutics market has been segmented into chemotherapy, chemoradiation and stent insertion. Based on region, the global market has been segmented into Latin America, North America, Asia-Pacific, Middle East & Africa, and Europe.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=bile-duct-cancer-therapeutics-market

Geographically, North America has been the largest market for bile duct cancer therapeutics. The growth of the regional market can be attributed to adequate reimbursement policies, greater awareness toward health care and advanced healthcare facilities. The Asia-Pacific and European markets for bile duct cancer therapeutics are projected to record strong CAGRs, over the forecast period.

Some of the key players in the global bile duct cancer therapeutics market include, Bayer, AG, Delcath Systems Inc., Senhwa Biosciences, Inc., PCI Biotech, Inc., ASLAN Pharmaceuticals, Inc., RedHill Biopharma Ltd. and Halozyme Therapeutics, Inc. among several others.

Read More

Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, Growth and Demand Forecast to 2023

The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants and designations. Thus, these regulatory bodies are amplifying the drug development process. 

Benign prostatic hyperplasia is also known as benign prostatic obstruction or benign prostatic hypertrophy, is a disease state in men, caused by prostate gland enlargement. Prostate develops in dual phase in entire life – the first phase occurs in initial phase of puberty, followed by the second phase that usually begins at the age of twenty-four and remains for most of a person’s life. Benign prostatic hyperplasia is a common problem in men aged above 50 years, and it occurs in the second phase of growth of prostate. However, the disease can also arise in men aged below 40 years, with the probabilities of its occurrence increasing with age.

Request to Get the Sample Pages at:

Aging population is the major factor on which the benign prostatic hyperplasia therapeutics market is mostly dependent. Asia-Pacific and European markets for benign prostatic hyperplasia therapeutics are likely to observe significant growth rates, during the forecast period, due to increase in aging population in these regions. The Latin American and North American markets for benign prostatic hyperplasia therapeutics are also projected to observe strong growth rates, during the forecast period.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=benign-prostatic-hyperplasia-therapeutics-market

Some of the key players operating in the global benign prostatic hyperplasia therapeutics market include Sandoz, Inc., Sanofi Aventis, Labopharm, Inc., Pfizer, Inc., and Teva Pharmaceuticals, Inc.

Read More

Acute Myeloid Leukemia (AML) Therapeutics Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The global acute myeloid leukemia therapeutics market is expected to witness notable growth, in the coming year due to increase in the new innovative and targeted drug delivery system. Various factors such as rising awareness regarding cancer treatments, increasing demand for safe and successful medications, rising incidence of cancer and technological advancements have been driving the growth of the global acute myeloid leukemia therapeutics market. Apart from this, various regulatory bodies are supporting the growth of the global market with funding, designations and grants, thereby accelerating the drug development process.

According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. Acute myeloid leukemia is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to prevent or fight infections.

Download Report Sample at:

The pipeline of acute myeloid leukemia contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully human monoclonal antibody, which helps to overcome the immunosuppressive effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is developing a Phase II drug candidate, Alisertib, for the treatment of acute myeloid leukemia. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-myeloid-leukemia-therapeutics-market

The acute myeloid leukemia therapeutics market was the largest market in the U.S. region of North America in year 2016, and it is expected to remain the largest during the forecast period due to large number of research and development activities.

Some of the key players operating in the acute myeloid leukemia therapeutics market include Celgene Corporation, Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG, Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Acute Lymphoblastic Leukemia (ALL) Therapeutics Market Share Assessments for the Regional and Country Level Segments

The global acute lymphoblastic leukemia therapeutics market is expected to witness considerable growth in the coming year since new drug formulations are proving to be the most effective treatment for cancer. An increasing awareness regarding cancer treatment, various technological advancements, high demand for safe and effective medications and high prevalence of cancer, are driving the growth of the global acute lymphoblastic leukemia therapeutics market. The regulatory bodies are also supporting the growth of the global market by providing funding, designations and grants to speed up the drug development process. 

The pipeline of acute lymphoblastic leukemia contains GRASPA (Erythrocytes Encapsulating L-asparaginase), a Phase I drug candidate of ERYtech Pharma, Inc. GRASPA is an encapsulated L-asparaginase product, using the company’s proprietary ERYCAPS platform technology for the treatment of acute lymphoblastic leukemia in adults and children. GRASPA causes systemic degradation of asparagine and inhibits the growth and survival of cancer cells.

Download Report Sample Copy at:   

Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine have been well established as a conventional method. Immunotherapy, combination therapy, monoclonal antibodies and steroids are showing good results for the treatment of acute lymphoblastic leukemia.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-lymphoblastic-leukemia-therapeutics-market

Geographically, North America is expected to be the largest market for acute lymphoblastic leukemia, owing to a large number of research and development activities, high healthcare expenditure, and increasing prevalence of cancer. According to National Cancer Institute, estimated new cases of acute lymphoblastic leukemia were 6,590 and estimated deaths were 1,430 in 2016, in the U.S. The U.S. contributed the largest revenue to the North American market in 2016, and it is expected to remain the largest market, globally, during the forecast period.

Some of the key players operating in the global acute lymphoblastic leukemia treatment market are Spectrum Pharmaceuticals, Inc., Sigma-Tau Pharmaceuticals, Inc., ERYtech Pharma, Pfizer, Inc., Amgen, and Takeda Pharmaceutical Company Limited.

Contact:

P&S Intelligence

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Gastrointestinal Over the Counter (OTC) Drugs Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The gastrointestinal over the counter drugs market is growing at a significant rate mainly due to increase in patient population. Strategic alliances are one the major trends that can be seen in the gastrointestinal over the counter drugs market and is supporting the market to grow at a more considerable rate.

Gastrointestinal diseases involve the gastrointestinal tract including stomach, esophagus, large intestine, small intestine, gallbladder, rectum, liver and pancreas. Over the counter (OTC) drugs are medications that are available without any prescription from the doctor. Over the counter drugs are chosen by regulatory agencies very carefully so as to ensure their efficacy and safety.

Request to Get the Sample Pages at: 

The gastrointestinal over the counter drugs can also be bought without any prescription of doctor. The gastrointestinal over the counter drugs are used for indications such as vomiting, gastro esophageal reflux disease (GERD), diarrhea, flatulence and constipation. The over the counter drugs are not compelled by regulatory guidelines, but they need to fulfill the drug monograph of a certain country.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=gastrointestinal-otc-drugs-market

In the U.S., the Food and Drug Administration regulates the manufacturing and sale of over the counter drugs. The Food and Drug Administration compels that all new drugs should obtain a new drug application (NDA) before it enters throughway, but the act excuse any drug which is recognized as effective and safe for the requirement. Some of the over the counter drugs approved in the U.S. are anti-microbial, sunscreens, anti fungal products, and internal and external analgesics. In the U.K., Medicines Regulations 2012 governs the medication. Medication in the country is categorized as a general sales list, prescription only medication and pharmacy medicines.

Some of the competitors in the gastrointestinal over the counter drugs market are Procter & Gamble, GlaxoSmithKline Pharmaceuticals Limited, Purdue Pharma L.P., Bayer AG, Boehringer Ingelheim GmbH, Johnson & Johnson Private Limited, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Reckitt Benckiser Group plc, C.B. Fleet Company, Inc., Perrigo Company plc, Sanofi, OMEGA SA, Abbott Laboratories, and Nestle SA.

Read More

Anti-Obesity Drugs Market Analysis by Top Companies, New Technology, Demand and Opportunity

The global anti-obesity drugs market is growing significantly, due to high prevalence of obesity and rich pipeline for anti-obesity drugs. The presence of large patient pool and massive unexplored market in the emerging economies, such as India and China, are creating ample opportunities for the growth of the global anti-obesity drugs market. The advanced research and development facilities, and new drug developments by the key players are propelling the demand for improved and cost-effective anti-obesity drugs, thus driving the growth of the global anti-obesity drugs market.

Obesity can be defined as a medical condition, in which excessive or abnormal accumulation of fat occurs in a patient. A person with body mass index (BMI) of 30 or above is considered obese. There are several factors causing obesity, such as eating habits, physical inactivity, and genetic makeup. Obesity has serious negative impact on an individual’s health. An obese individual is at a higher risk of developing chronic diseases, such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders. According to the WHO, in 2014, there were 600 million obese people aged 18 years or above, which accounted for 13% of the total adult population in the world. The prevalence of obesity is the highest in the U.S. According to the Center for Disease Control and Prevention (CDC), in the U.S., 35.1% of the adult population aged 20 years or above were obese during 2011 - 2012.

Request to Get the Sample Pages at: 

Geographically, North America leads the global anti-obesity drugs market, due to high incidences of obesity, high healthcare expenditure, and increased awareness about obesity and obesity related risks among patients. In addition, the increasing involvement of government and non-government organizations to educate and aware people about the ill effects of obesity, and extensive research and development activities for the development of anti-obesity drugs are fueling the growth of the anti-obesity drugs market in North America. Asia-Pacific is the fastest growing region in the global anti-obesity drugs market. The fastest growth of the region is attributed to improving healthcare infrastructure, growing healthcare expenditure and increasing geriatric population. Moreover, the anti-obesity drugs market is growing due to increasing research and development facilities, growing disposable income, and presence of large patient pool in the emerging countries, such as India and China.

Some of the major players operating in the global anti-obesity drugs market are F. Hoffmann-La Roche AG, Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceuticals Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen, Rhythm Pharmaceuticals, Zydus Cadila, and Norgine B.V.

Read More..

Read More